

David J Macewan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3774066/david-j-macewan-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

5,714
citations

36
h-index

75
g-index

89
ext. papers

6,604
ext. citations

5.2
avg, IF

5.79
L-index

#	Paper	IF	Citations
79	Characterization of a high throughput human stem cell cardiomyocyte assay to predict drug-induced changes in clinical electrocardiogram parameters. <i>European Journal of Pharmacology</i> , 2021 , 912, 174584	5.3	0
78	The importance of Ras in drug resistance in cancer. <i>British Journal of Pharmacology</i> , 2021 ,	8.6	7
77	Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. <i>Biochemical Pharmacology</i> , 2021 , 183, 114348	6	4
76	Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. <i>Clinical Cancer Research</i> , 2021 , 27, 5647-5659	12.9	0
75	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors. <i>British Journal of Pharmacology</i> , 2021 , 178 Suppl 1, S264-S312	8.6	16
74	HLA Class-II-Restricted CD8 T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2412-2425.e2	4.3	4
73	A functionally defined high-density NRF2 interactome reveals new conditional regulators of ARE transactivation. <i>Redox Biology</i> , 2020 , 37, 101686	11.3	4
72	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors. <i>British Journal of Pharmacology</i> , 2019 , 176 Suppl 1, S247-S296	8.6	127
71	Apoptosis of Leukemia Cells by Ocimum basilicum Fractions Following TNF alpha Induced Activation of JNK and Caspase 3. <i>Current Pharmaceutical Design</i> , 2019 , 25, 3681-3691	3.3	2
70	New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome. <i>Cancer Research</i> , 2018 , 78, 15-29	10.1	81
69	Gene Editing of BTK in Acute Myeloid Leukaemia Using CRISPR-Cas9. <i>Blood</i> , 2018 , 132, 3952-3952	2.2	2
68	MicroRNAs in Therapy and Toxicity. <i>Methods in Pharmacology and Toxicology</i> , 2017 , 155-167	1.1	1
67	Ibrutinib inhibits BTK-driven NF- κ B p65 activity to overcome bortezomib-resistance in multiple myeloma. <i>Cell Cycle</i> , 2015 , 14, 2367-75	4.7	36
66	Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. <i>Lancet Haematology</i> , 2015 , 2, e204-11	14.6	14
65	TWEAKing for a fight with GVHD. <i>Blood</i> , 2015 , 126, 429-30	2.2	2
64	Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia. <i>Scientific Reports</i> , 2015 , 5, 12949	4.9	24
63	Oxidative stress responses and NRF2 in human leukaemia. <i>Oxidative Medicine and Cellular Longevity</i> , 2015 , 2015, 454659	6.7	41

62	Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. <i>Blood</i> , 2014 , 123, 1229-38	2.2	80
61	Understanding life and death decisions in human leukaemias. <i>Biochemical Society Transactions</i> , 2014 , 42, 747-51	5.1	
60	Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. <i>Oncotarget</i> , 2014 , 5, 9930-8	3.3	51
59	BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF- κ B. <i>Cellular Signalling</i> , 2013 , 25, 106-12	4.9	85
58	Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. <i>Cell Cycle</i> , 2013 , 12, 2144-53	4.7	55
57	Understanding the role of NRF2-regulated miRNAs in human malignancies. <i>Oncotarget</i> , 2013 , 4, 1130-423.3	3.3	48
56	The high Nrf2 expression in human acute myeloid leukemia is driven by NF- κ B and underlies its chemo-resistance. <i>Blood</i> , 2012 , 120, 5188-98	2.2	175
55	Micro RNAs as a new therapeutic target towards leukaemia signalling. <i>Cellular Signalling</i> , 2012 , 24, 363-368	3.3	16
54	Bortezomib induces heme oxygenase-1 expression in multiple myeloma. <i>Cell Cycle</i> , 2012 , 11, 2248-52	4.7	35
53	Understanding the role of miRNA in regulating NF- κ B in blood cancer. <i>American Journal of Cancer Research</i> , 2012 , 2, 65-74	4.4	12
52	Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. <i>Oncotarget</i> , 2011 , 2, 658-68	3.3	59
51	TNF mediates the sustained activation of Nrf2 in human monocytes. <i>Journal of Immunology</i> , 2011 , 187, 702-7	5.3	55
50	Silencing FLIP(L) modifies TNF-induced apoptotic protein expression. <i>Cell Cycle</i> , 2011 , 10, 1067-72	4.7	6
49	High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. <i>Cancer Research</i> , 2011 , 71, 1999-2009	10.1	73
48	The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. <i>Cancers</i> , 2011 , 3, 1605-21	6.6	38
47	NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. <i>Cancer Research</i> , 2010 , 70, 2973-83	10.1	58
46	FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. <i>Oncotarget</i> , 2010 , 1, 359-366	3.3	28
45	FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. <i>Oncotarget</i> , 2010 , 1, 359-66	3.3	15

44	TNF signaling gets FLIPped off: TNF-induced regulation of FLIP. <i>Cell Cycle</i> , 2008 , 7, 194-9	4.7	9
43	Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. <i>Journal of Immunology</i> , 2008 , 181, 6730-7	5.3	153
42	HO-1 underlies resistance of AML cells to TNF-induced apoptosis. <i>Blood</i> , 2008 , 111, 3793-801	2.2	107
41	Interactions between TNF and GnRH. <i>Neurochemical Research</i> , 2008 , 33, 678-82	4.6	15
40	TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. <i>Cellular Signalling</i> , 2007 , 19, 1238-48	4.9	158
39	Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 12790-5	11.5	36
38	Influx of extracellular Ca ²⁺ is necessary for electrotaxis in Dictyostelium. <i>Journal of Cell Science</i> , 2006 , 119, 4741-8	5.3	48
37	Pore forming polyalkylpyridinium salts from marine sponges versus synthetic lipofection systems: distinct tools for intracellular delivery of cDNA and siRNA. <i>BMC Biotechnology</i> , 2006 , 6, 6	3.5	20
36	Switching leukemia cell phenotype between life and death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 12940-5	11.5	26
35	Distinct regulation of cytosolic phospholipase A2 phosphorylation, translocation, proteolysis and activation by tumour necrosis factor-receptor subtypes. <i>Biochemical Journal</i> , 2003 , 374, 453-61	3.8	43
34	Modulation by caspases of tumor necrosis factor-stimulated c-Jun N-terminal kinase activation but not nuclear factor-kappaB signaling. <i>Biochemical Pharmacology</i> , 2003 , 65, 91-9	6	11
33	The influence of alkyl pyridinium sponge toxins on membrane properties, cytotoxicity, transfection and protein expression in mammalian cells. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003 , 1614, 171-81	3.8	28
32	Tumor necrosis factor-alpha-induced activation of RhoA in airway smooth muscle cells: role in the Ca ²⁺ sensitization of myosin light chain20 phosphorylation. <i>Molecular Pharmacology</i> , 2003 , 63, 714-21	4.3	87
31	TNF receptor subtype signalling: differences and cellular consequences. <i>Cellular Signalling</i> , 2002 , 14, 477-92	4.9	505
30	TNF ligands and receptors--a matter of life and death. <i>British Journal of Pharmacology</i> , 2002 , 135, 855-758.6		260
29	Tumour necrosis factor-induced activation of c-Jun N-terminal kinase is sensitive to caspase-dependent modulation while activation of mitogen-activated protein kinase (MAPK) or p38 MAPK is not. <i>Biochemical Journal</i> , 2002 , 366, 145-55	3.8	21
28	Differential activation of nuclear factor-kappaB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly. <i>FEBS Letters</i> , 2002 , 515, 119-26	3.8	70
27	Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. <i>Biochemical Journal</i> , 2001 , 359, 525-35	3.8	39

26	Type II tumour necrosis factor- α receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. <i>Biochemical Journal</i> , 2001 , 359, 525-535	3.8	58
25	Stimulation of stress-activated but not mitogen-activated protein kinases by tumour necrosis factor receptor subtypes in airway smooth muscle. <i>Biochemical Pharmacology</i> , 2001 , 61, 749-59	6	25
24	Modulated kinase activities in cells undergoing tumour necrosis factor-induced apoptotic cell death. <i>FEBS Letters</i> , 2001 , 505, 68-74	3.8	11
23	Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. <i>Neuropharmacology</i> , 2001 , 40, 221-32	5.5	158
22	Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. <i>Journal of Neuroscience</i> , 2001 , 21, 2425-33	6.6	138
21	Selective down-regulation of the G(q)alpha/G11alpha G-protein family in tumour necrosis factor-alpha induced cell death. <i>Molecular and Cellular Biochemistry</i> , 2000 , 206, 67-74	4.2	18
20	Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. <i>Journal of Biological Chemistry</i> , 1999 , 274, 9539-47	5.4	75
19	Tumour necrosis factor-alpha activates a calcium sensitization pathway in guinea-pig bronchial smooth muscle. <i>Journal of Physiology</i> , 1999 , 518 (Pt 2), 561-9	3.9	61
18	Protein kinase C isoforms in pituitary cells displaying differential sensitivity to phorbol ester. <i>Molecular and Cellular Biochemistry</i> , 1999 , 202, 85-90	4.2	12
17	Selective activation by tumour necrosis factor- α receptor subtypes of cytosolic phospholipase A2 in CrmA-expressing cells. <i>Biochemical Society Transactions</i> , 1999 , 27, A112-A112	5.1	
16	Elevated cPLA2 levels as a mechanism by which the p70 TNF and p75 NGF receptors enhance apoptosis. <i>FEBS Letters</i> , 1996 , 379, 77-81	3.8	43
15	Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. <i>FEBS Letters</i> , 1996 , 399, 108-12	3.8	30
14	Agonist regulation of adenylate cyclase activity in neuroblastoma x glioma hybrid NG108-15 cells transfected to co-express adenylate cyclase type II and the beta 2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptor-mediated stimulation of adenylate cyclase activity. <i>Biochemical Journal</i> , 1996 , 318 (Pt 3), 1033-9	3.8	38
13	Phorbol ester and diacylglycerol activation of native protein kinase C species from various tissues. <i>Molecular and Cellular Biochemistry</i> , 1995 , 146, 127-37	4.2	13
12	Degradation of G11 alpha/Gq alpha is accelerated by agonist occupancy of alpha 1A/D, alpha 1B, and alpha 1C adrenergic receptors. <i>Journal of Biological Chemistry</i> , 1995 , 270, 17196-203	5.4	32
11	The differential effects of protein kinase C activators and inhibitors on rat anterior pituitary hormone release. <i>Molecular and Cellular Endocrinology</i> , 1993 , 94, 223-34	4.4	25
10	Biochemical characterisation of an apparently novel isoform of protein kinase C in pituitary. <i>Biochemical Society Transactions</i> , 1993 , 21, 386S	5.1	5
9	Evidence that protein kinase C alpha has reduced affinity towards 1,2-dioctanoyl-sn-glycerol: the effects of lipid activators on phorbol ester binding and kinase activity. <i>European Journal of Pharmacology</i> , 1993 , 246, 9-18		7

8	Evidence for a distinct H7-resistant form of protein kinase C in rat anterior pituitary gland. <i>FEBS Letters</i> , 1993 , 329, 199-204	3.8	11
7	Characterisation of protein kinase C isoforms and enzymic activity from the alpha T3-1 gonadotroph-derived cell line. <i>FEBS Letters</i> , 1993 , 333, 67-72	3.8	30
6	Properties and [32P] phosphorylation targets of a novel form of protein kinase C in pituitary. <i>Biochemical Society Transactions</i> , 1992 , 20, 133S	5.1	7
5	Protein kinase C-dependent and -independent actions of arachidonic acid in GH3 cells. <i>Biochemical Society Transactions</i> , 1991 , 19, 115S	5.1	
4	Differential activation of phospholipase A2 by protein kinase C in pituitary cells. <i>Biochemical Society Transactions</i> , 1991 , 19, 117S	5.1	5
3	Calcium influx through L-type channels into rat anterior pituitary cells can be modulated in two ways by protein kinase C (PKC-isoform selectivity of 1,2-dioctanoyl sn-glycerol?). <i>FEBS Letters</i> , 1991 , 291, 79-83	3.8	14
2	Inhibition of depolarisation-induced calcium influx into GH3 cells by arachidonic acid: the involvement of protein kinase C. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1991 , 1094, 346-54	4.9	7
1	Biological activity of some thyrotrophin-releasing hormone analogues substituted at the 2 position. <i>Biochemical Society Transactions</i> , 1990 , 18, 433-4	5.1	1